VEN 307 — Competitive Intelligence Brief

VEN 307 (VEN 307) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Rho kinase inhibitor. Area: Ophthalmology.

phase 3 Rho kinase inhibitor Rho kinase (ROCK) Ophthalmology Small molecule

Target snapshot

VEN 307 (VEN 307) — Ventrus Biosciences, Inc. VEN 307 is a topical ophthalmic agent designed to reduce intraocular pressure in glaucoma by enhancing aqueous humor outflow.

Comparator set (4 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
VEN 307 TARGET	VEN 307	Ventrus Biosciences, Inc	phase 3	Rho kinase inhibitor	Rho kinase (ROCK)
Rhopressa	NETARSUDIL	Alcon Labs Inc	marketed	Rho Kinase Inhibitor	rho kinase	2017-01-01
Rocklatan 0.02%-0.005% Ophthalmic Solution	Rocklatan 0.02%-0.005% Ophthalmic Solution	Eye Centers of Southeast Texas	marketed	Prostaglandin analog / Rho kinase inhibitor combination	Prostaglandin F receptor (FP receptor) / Rho kinase (ROCK)
Netarsudil Ophthalmic	Netarsudil Ophthalmic	University of the Incarnate Word	marketed	Rho kinase inhibitor	ROCK1/ROCK2, norepinephrine transporter
DE-114 ophthalmic solution	DE-114 ophthalmic solution	Santen Pharmaceutical Co., Ltd.	phase 3	Rho kinase inhibitor	ROCK (Rho-associated coiled-coil containing protein kinase)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Rho kinase inhibitor class)

1. GlaxoSmithKline · 1 drug in this class
2. Santen Pharmaceutical Co., Ltd. · 1 drug in this class
3. University of the Incarnate Word · 1 drug in this class
4. Ventrus Biosciences, Inc · 1 drug in this class